Company Overview and News

 
Company news: Genesys International Corporation

2018-05-17 thehindubusinessline
A consortium led by Genesys International Corporation has bagged an order worth $450,000 (about ₹3 crore) from TAPI Pipeline Company. Genesys is executing the project, along with its local partner Afghanite, wherein it will conduct a route survey and mapping through airborne LiDAR terrestrial and bathymetric survey for the Afghanistan stretch of about 800 km, as part of the Turkmenistan - Afghanistan - Pakistan - India (TAPI) Gas Pipeline Project.

 
MCA identifies 18 more shell cos which together deposited Rs 10,000 cr cash post DeMo

2017-11-27 moneycontrol
The Ministry of Corporate Affairs (MCA) has prepared the second list of 18 companies which deposited unusually large sums of cash in their bank accounts soon after demonetisation.

 
IMPAL, Garden Silks results on Tuesday

2017-11-20 thehindubusinessline
Around one dozen companies will announce their quarterly results for the period September 30 on Tuesday.

 
Bridge India Fund sells 1.75 lakh shares of Genesys International Corporation

2017-10-14 moneycontrol
On October 13, 2017 Bridge India Fund sold 175,000 shares of Genesys International Corporation at Rs 363.39 per share on the NSE.

 
Genesys International Corporation allots 51,200 equity shares

2017-04-25 indiainfoline
Disclaimer: The contents herein is specifically prepared by ‘Dalal Street Investment Journal’, and is for your information & personal consumption only. India Infoline Limited or Dalal Street Investment Journal do not guarantee the accuracy, correctness, completeness or reliability of information contained herein and shall not be held responsible.

 
Genesys International Corporation allots 160700 equity shares

2017-03-07 indiainfoline
Disclaimer: The contents herein is specifically prepared by ‘Dalal Street Investment Journal’, and is for your information & personal consumption only. India Infoline Limited or Dalal Street Investment Journal do not guarantee the accuracy, correctness, completeness or reliability of information contained herein and shall not be held responsible.

 
Top buzzing midcap stocks to trade on January 19

2017-01-19 moneycontrol
Ensure that your correct email id and mobile has been registered with moneycontrol. If not, please update your profile and secure the account now. Updating your email id and mobile number offers following benefits:

 
Genesys bags order from MCGM; stock up by 8.43%

2017-01-19 indiainfoline
Genesys International is having a fruitful day on the bourses. The stock has witnessed a spurt in volumes by more than 2.09 times. The stock traded at its new 52 week high and has gained 10.06% intraday.

 
Genesys International gains 11%, bags Rs 65 cr order from MCGM

2017-01-19 moneycontrol
Ensure that your correct email id and mobile has been registered with moneycontrol. If not, please update your profile and secure the account now. Updating your email id and mobile number offers following benefits:

Related Articles

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

2018-05-21 - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...

SQ: Square Analysis and Research Report

2018-05-21 - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...